Racine Michael S, Symons Kathy V, Foster Carol M, Barkan Ariel L
Division of Endocrinology and Metabolism, 3920 Taubman Center, Box 0354, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
J Clin Endocrinol Metab. 2004 Jul;89(7):3326-31. doi: 10.1210/jc.2003-031948.
The increase in pituitary GH secretion that occurs during mid-late puberty in boys follows an increase in circulating testosterone (T) concentration; the direct mechanism by which this occurs is unknown. We hypothesized that T increases GH secretion during puberty by augmenting hypothalamic output of GHRH. Using constant infusions of a GHRH antagonist, we tested this hypothesis in six early pubertal boys with constitutional delay of growth and adolescence who had a mean chronological age of 14.0 +/- 0.3 yr and mean bone age of 11.4 +/- 0.2 yr. Blood samples were obtained from subjects every 15 min for 24 h during the overnight infusion of normal saline (2000-0600 h) and again during the overnight infusion of GHRH antagonist (0.33 microg/kg/h) the following night. Subjects then received transdermal T (5-mg patch) for 12 h nightly and were studied again after 4 wk of treatment. Serum samples were assayed for GH and total ghrelin; the percent suppression of GH during GHRH antagonist infusion was calculated. Morning serum T rose from 0.44 +/- 0.09 to 4.43 +/- 0.74 microg/liter (P = 0.005). T treatment was associated with a 92.6% increase in mean nocturnal GH secretion area under the curve (830 +/- 177 to 1599 +/- 340 microg/24 h.liter). Infusion of GHRH-antagonist suppressed mean nocturnal GH area under the curve by 29.1% before T treatment (830 +/- 177 to 621 +/- 168 microg/24 h.liter), and by 29.4% after T treatment (1599 +/- 340 to 1182 +/- 249 microg/24 h.liter; P = 0.99). Somatotroph sensitivity to GHRH was tested with 0.1- and 1.0-microg/kg doses of GHRH-44 iv; GH response did not change with regard to T treatment. The mean 24-h concentration of total ghrelin was unchanged with regard to T treatment. In summary, nightly transdermal T administration in six boys with constitutional delay of growth and adolescence increased GH output almost 2-fold, whereas the degree of GH suppressibility by GHRH antagonist remained unchanged. We conclude that the T-associated augmentation of GH secretion during early puberty in boys is unlikely to involve an absolute increase in hypothalamic GHRH output.
男孩青春期中后期垂体生长激素(GH)分泌增加与循环睾酮(T)浓度升高有关;其发生的直接机制尚不清楚。我们推测,在青春期,T通过增加下丘脑生长激素释放激素(GHRH)的输出量来增加GH分泌。我们使用持续输注GHRH拮抗剂的方法,对6名青春期发育延迟的男孩进行了测试,这些男孩的实际年龄平均为14.0±0.3岁,骨龄平均为11.4±0.2岁。在夜间输注生理盐水(2000 - 0600时)的24小时内,每15分钟从受试者采集一次血样,次日夜间输注GHRH拮抗剂(0.33微克/千克/小时)时同样如此。之后,受试者每晚接受经皮T(5毫克贴片)治疗12小时,治疗4周后再次进行研究。检测血清样本中的GH和总胃饥饿素;计算GHRH拮抗剂输注期间GH的抑制百分比。早晨血清T从0.44±0.09微克/升升至4.43±0.74微克/升(P = 0.005)。T治疗使夜间GH分泌曲线下平均面积增加了92.6%(从830±177微克/24小时·升增至1599±340微克/24小时·升)。在T治疗前,输注GHRH拮抗剂使夜间GH曲线下平均面积降低了29.1%(从830±177微克/24小时·升降至621±168微克/24小时·升),T治疗后降低了29.4%(从1599±340微克/24小时·升降至1182±249微克/24小时·升;P = 0.99)。用0.1微克/千克和1.0微克/千克剂量的GHRH - 44静脉注射测试生长激素细胞对GHRH的敏感性;GH反应在T治疗前后没有变化。T治疗后,总胃饥饿素的平均24小时浓度没有改变。总之,对6名青春期发育延迟的男孩每晚进行经皮T给药,使GH输出量增加了近2倍,而GHRH拮抗剂对GH的抑制程度保持不变。我们得出结论,男孩青春期早期与T相关的GH分泌增加不太可能涉及下丘脑GHRH输出量的绝对增加。